Illumina (NASDAQ:ILMN) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Friday, January 5th.
ILMN has been the subject of several other reports. Barclays boosted their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price for the company in a report on Friday, October 27th. Canaccord Genuity reaffirmed a “buy” rating and issued a $230.00 price target (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $226.00 price target (up from $202.00) on shares of Illumina in a research report on Monday, October 9th. Finally, Janney Montgomery Scott raised Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $214.38.
Illumina (NASDAQ:ILMN) traded up $4.68 on Friday, reaching $244.72. The company had a trading volume of 975,763 shares, compared to its average volume of 900,526. Illumina has a 12-month low of $156.50 and a 12-month high of $245.96. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The firm has a market cap of $35,730.00, a price-to-earnings ratio of 46.17, a P/E/G ratio of 3.23 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. During the same period in the previous year, the company earned $0.97 EPS. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. research analysts expect that Illumina will post 3.76 EPS for the current year.
In other news, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total transaction of $283,187.50. Following the sale, the director now directly owns 9,088 shares in the company, valued at $2,058,886.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $210.43, for a total value of $4,208,600.00. Following the sale, the director now owns 539,176 shares in the company, valued at $113,458,805.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,671 shares of company stock worth $29,485,768. 0.89% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in ILMN. Advisory Services Network LLC grew its position in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the period. Dupont Capital Management Corp bought a new stake in Illumina in the third quarter valued at $153,000. Patten Group Inc. grew its position in Illumina by 71.1% in the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after acquiring an additional 615 shares during the period. West Coast Financial LLC bought a new stake in Illumina in the third quarter valued at $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in Illumina in the second quarter valued at $226,000. Hedge funds and other institutional investors own 91.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.